Participation of angiotensin II and bradykinin in contractile function in dog stunned myocardium

European Journal of Pharmacology

Volumn 382, Issue 3, 1999, Pages 187-196

  Nakai, Tohru ^a   Satoh, Kumi ^a   Kosugi, Tetsuro ^a   Hoshi, Katsuji ^a   Ichihara, Kazuo ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

BIBR 277; Enalapril; Hoe 140; Myocardial stunning

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; ENALAPRIL; ICATIBANT; TELMISARTAN;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; FEMALE; HEART CONTRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANESTHESIA; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BRADYKININ; CORONARY CIRCULATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; FEMALE; HEART RATE; LIGATION; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION; MYOCARDIAL STUNNING; RECEPTORS, BRADYKININ; TIME FACTORS; VENTRICULAR PRESSURE;

EID: 0032713246     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00586-5     Document Type: Article

References (29)

1. Barbe F., Su J.B., Guyene T.T., Crozatier B., Ménard J., Hittinger L. Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. Am. J. Physiol. 270:1996;H1985-H1992.
2. Bergmeyer H.-U. Methods of Enzymatic Analysis. 1974;Academic Press, New York, NY.
3. Blais C. Jr., Drapeau G., Raymond P., Lamontagne D., Gervais N., Venneman I., Adam A. Contribution of angiotensin converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am. J. Physiol. 273:1997;H2263-H2271.
4. Brown K. Angiotensin receptors are implicated in the mechanism of mass action. Trends Pharmacol. Sci. 10:1989;87-89.
5. Erdos E.G., Skidgel R.A. The angiotensin I converting enzyme. Lab. Invest. 56:1987;345-348.
6. Ertl G. Angiotensin converting enzyme inhibitors and ischemic heart disease. Eur. Heart J. 9:1988;716-727.
7. Ertl G., Kloner R.A., Alexander R.W., Braunwald E. Limitation of experimental infarct size by an angiotensin converting enzyme inhibitor. Circulation. 65:1982;40-48.
8. Gavras H., Kremer D., Brown J.J. Angiotensin and norepinephrine induced myocardial lesions; experimental and clinical studies in rabbits and man. Am. Heart J. 89:1975;321-332.
9. Gondo M., Maruta H., Arakawa K. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jpn. Heart J. 30:1989;219-229.
10. Goto M., Liu Y., Ardell J.L., Cohen M.V., Downey J.M. Bradykinin limits myocardial infarction in rabbits by protein kinase C activation and not by nitric oxide synthesis. Circulation. 90(Suppl. I):1995;I 208.
11. Hock F.J., Wirth K., Albus U., Linz W., Gerhards H.J., Wiemer G., Henke S., Breipohl G., König W., Knolle J., Schölkens B.A. Hoe-140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102:1991;769-773.
12. Ichihara K., Abiko Y. Difference between endocardial and epicardial utilization of glycogen in the ischemic heart. Am. J. Physiol. 229:1975;1585-1589.
13. Izumi H., Nakai T., Kano S., Hoshi K., Ichihara K. Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs. Coronary Artery Disease. 7:1996;775-779.
14. Katoh Y., Komuro I., Shibasaki Y., Yamaguchi H., Yazaki Y. Angiotensin II induces hypertrophy and oncogene expression in cultured rat heart myocytes. Circulation. 80(Suppl. II):1989;II 450.
15. Kinoshita A., Uratu H., Bunpus F.M., Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from human heart. J. Biol. Chem. 266:1991;19192-19197.
16. Kitakaze M., Minamino T., Node K., Komamura K., Shinozaki Y., Mori H., Kosaka H., Inoue M., Hori M., Kamada T. Beneficial effects of inhibition of angiotensin converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation. 92:1995;950-961.
17. Liang C., Gavras H., Black J., Sherman L.G., Hood W.B. Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation. 66:1982;1249-1255.
18. Mcalpine H.M., Cobbe S.M. Neuroendocrine change in acute myocardial infarction. Am. J. Med. 84(Suppl. 3A):1988;61-66.
19. Noda K., Sasaguri M., Ideishi M., Ikeda M., Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc. Res. 27:1993;334-340.
20. Okunishi H., Miyazaki M., Okamura T., Toda N. Different distribution of two types of angiotensin-generating enzymes in the aortic wall. Biochem. Biophys. Res. Commun. 149:1987;1186-1192.
21. Packer M. Converting enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concept. J. Cardiovasc. Pharmacol. 10(Suppl. 7):1987;S83-S87.
22. Pelc L.R., Garrett J.G., David C.W. Mechanism of coronary vasodilation produced by bradykinin. Circulation. 83:1991;2048-2056.
23. Przyklenk K., Kloner R.A. Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury. Br. J. Clin. Pharmacol. 28:1989;167S-175S. Suppl.
24. Robertson J.I.S., Tillman D.M. Converting enzyme inhibitors in the treatment of hypertension. J. Cardiovasc. Pharmacol. 10(Suppl. 7):1987;S43-S48.
25. Schölkens B.A., Linz W., Lindpaintner K., Ganten D. Angiotensin deteriorates but bradykinin improves cardiac function following ischemia in isolated rat hearts. J. Hypertens. 5(Suppl. 5):1987;S7-S9.
26. Vegh A., Szekeres L., Parratt J.R. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anesthetized dogs. Br. J. Pharmacol. 104:1991;294-295.
27. Wienen W., Hauel N., Van Meel J.C.A., Narr B., Ries U., Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR-277. Br. J. Pharmacol. 110:1993;245-252.
28. Wirth K., Hock F.J., Albus U., Linz W., Alpermann H.G., Anagnostopoulos H., Henke St., Breipohl G., König W., Knolle J., Schölkens B.A. Hoe-140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 102:1991;774-777.
29. Yoshiyama M., Kim S., Yamagishi H., Omura T., Tani T., Yanagi S., Toda I., Teragaki M., Akioka K., Takeuchi K., Takeda T. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am. Heart J. 128:1994;1-6.